AKT1 and neoplasm: Previously, we reported that the orally bioavailable Akt inhibitor, AZD5363, potently induces autophagy39 and hence is used here to assess in vivo effects of CLU inhibition (with OGX-011) on treatment-induced autophagy and tumour growth.